The week in pharma: action, reaction and insight – week to March 3, 2023

5 March 2023

By Barbara Obstoj-Cardwell. Editor

New clinical research news last week included USA-based Blueprint Medicines on Monday releasing promising data on its Ayvakit in the treatment of indolent systemic mastocytosis. On Friday, US drug developer Exelixis announced that a Phase III trial of its Cabometyx in kidney cancer failed. On the regulatory front, Germany’s Bayer gained expanded approval for its oncology drug Nubeqa in Japan for the indication of metastatic prostate cancer, and last Wednesday the US Food and Drug Administration (FDA) granted approval for Reata Pharmaceuticals’ Skyclarys (omaveloxolone) as a treatment for Friedreich’s ataxia. Also of note, there were media reports that Pfizer had stepped in where fellow US pharma giant Merck & Co had failed, entering early-stage talks to acquire US biotech firm Seagen.

Ayvakit data leaves room for bezuclastinib differentiation

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK